Creative Planning reduced its stake in shares of Allergan plc (NYSE:AGN) by 7.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,801 shares of the company’s stock after selling 1,460 shares during the quarter. Creative Planning’s holdings in Allergan were worth $3,076,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of AGN. Beach Investment Management LLC. increased its stake in Allergan by 845.2% during the second quarter. Beach Investment Management LLC. now owns 93,195 shares of the company’s stock worth $22,655,000 after acquiring an additional 83,335 shares during the last quarter. Atlantic Trust Group LLC increased its stake in Allergan by 0.7% during the second quarter. Atlantic Trust Group LLC now owns 649,290 shares of the company’s stock worth $157,836,000 after acquiring an additional 4,647 shares during the last quarter. Guyasuta Investment Advisors Inc. grew its stake in shares of Allergan by 1.1% during the second quarter. Guyasuta Investment Advisors Inc. now owns 78,693 shares of the company’s stock valued at $19,129,000 after buying an additional 874 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. grew its stake in shares of Allergan by 18.4% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 333,184 shares of the company’s stock valued at $80,994,000 after buying an additional 51,725 shares during the last quarter. Finally, WMS Partners LLC bought a new position in shares of Allergan during the second quarter valued at approximately $921,000. 81.18% of the stock is currently owned by institutional investors.
Allergan plc (NYSE AGN) opened at $181.33 on Monday. Allergan plc has a 52 week low of $160.07 and a 52 week high of $256.80. The stock has a market capitalization of $60,307.29, a P/E ratio of -8.06, a P/E/G ratio of 1.33 and a beta of 1.11. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.40.
Allergan (NYSE:AGN) last announced its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.06 by $0.09. Allergan had a positive return on equity of 8.00% and a negative net margin of 47.27%. The company had revenue of $4.03 billion for the quarter, compared to analysts’ expectations of $4.04 billion. During the same quarter in the prior year, the firm earned $3.32 earnings per share. Allergan’s revenue was up 11.4% compared to the same quarter last year. analysts expect that Allergan plc will post 16.27 EPS for the current year.
Allergan announced that its board has authorized a share repurchase program on Monday, September 25th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.
A number of research analysts have recently commented on AGN shares. Royal Bank of Canada cut their target price on Allergan from $285.00 to $277.00 and set an “outperform” rating on the stock in a research note on Monday, September 25th. Mizuho reaffirmed a “buy” rating and set a $267.00 target price on shares of Allergan in a research note on Monday, September 25th. Credit Suisse Group reaffirmed an “outperform” rating and set a $266.00 target price (down previously from $286.00) on shares of Allergan in a research note on Tuesday, September 26th. UBS Group reaffirmed a “buy” rating and set a $275.00 target price on shares of Allergan in a research note on Tuesday, September 26th. Finally, Barclays reaffirmed an “equal weight” rating on shares of Allergan in a research note on Monday, October 2nd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $226.95.
In related news, Chairman Brent L. Saunders bought 4,600 shares of the stock in a transaction on Wednesday, December 6th. The stock was bought at an average price of $164.74 per share, for a total transaction of $757,804.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider William Meury sold 11,807 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $173.89, for a total value of $2,053,119.23. The disclosure for this sale can be found here. In the last three months, insiders purchased 17,630 shares of company stock worth $2,890,057. 0.36% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: This piece was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.thelincolnianonline.com/2018/01/22/creative-planning-has-3-08-million-holdings-in-allergan-plc-agn.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.